MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

0.76 2.7

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.7

Max

0.79

Põhinäitajad

By Trading Economics

Sissetulek

31M

-34M

Müük

25M

27M

Aktsiakasum

-0.09

Kasumimarginaal

-127.16

Töötajad

103

EBITDA

30M

-30M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+646.27% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

102M

208M

Eelmine avamishind

-1.94

Eelmine sulgemishind

0.76

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. nov 2024, 12:42 UTC

Suurimad hinnamuutused turgudel

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

646.27% tõus

12 kuu keskmine prognoos

Keskmine 5 USD  646.27%

Kõrge 6 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.501 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.